Core Insights - Genelux Corporation is entering a pivotal period in 2026 with key clinical readouts for Olvi-Vec, particularly from the Phase 3 OnPrime/GOG-3076 trial expected in the second half of the year [2] - Interim data from systemic lung cancer trials show promising results, with partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC) [2][3] - The company appointed Jason Litten, M.D., as Chief Medical Officer to lead the clinical development strategy [6] - As of December 31, 2025, the company reported $33.1 million in pro forma cash and equivalents, expected to support operations into the first quarter of 2027 [8] Clinical Development - The ongoing Phase 3 OnPrime/GOG-3076 trial is evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and bevacizumab for platinum-resistant/refractory ovarian cancer, with topline data anticipated in the second half of 2026 [4] - Interim results from the SCLC Phase 1b/2 trial showed a 33% partial response rate among patients, with a disease control rate of 67% [10] - The Phase 2 VIRO-25 trial in NSCLC reported a 60% disease control rate, with tumor size changes observed [10] Financial Performance - For the year ended December 31, 2025, Genelux reported a net loss of $32.1 million, or $0.86 per share, compared to a net loss of $29.9 million, or $0.95 per share, for 2024 [11][17] - Research and development expenses increased to $19.9 million in 2025 from $19.0 million in 2024, primarily due to higher clinical trial costs [9] - General and administrative expenses rose to $13.4 million in 2025 from $12.7 million in 2024, driven by increased employee compensation [10] Business Updates - The company successfully closed an underwritten public offering in January 2026, raising $18.5 million in net proceeds, which will be used for general corporate purposes [7] - The appointment of Jason Litten, M.D., as Chief Medical Officer is expected to enhance the company's clinical development strategy, leveraging his extensive experience in clinical trials [6]

Core Insights - Calidi Biotherapeutics is hosting a webinar on November 19, 2025, to discuss its innovative approach to precision genetic medicine using the RedTail platform [1][2] - The RedTail platform is designed to deliver genetic medicines to metastatic tumor sites while avoiding immune detection, showcasing promising preclinical data [2][3] - The oncology market is projected to exceed $560 billion by 2033, presenting significant growth opportunities for Calidi [3] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to distal disease sites [1][6] - The proprietary RedTail platform utilizes an engineered enveloped oncolytic virus for systemic delivery, aiming to effectively reach tumor sites and induce tumor lysis [6][7] - The lead candidate from the RedTail platform targets non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7] Financial Position - The third quarter 2025 earnings report indicated a strengthened balance sheet with reduced debt and an increased cash balance, alongside a decrease in general and administrative spending [3]

Group 1 - Compugen Ltd. (NASDAQ: CGEN) is an immuno-oncology biotech utilizing its Unigen platform for discovering immune checkpoints, drug candidates, and biomarkers [1] - The Unigen platform is based on Artificial Intelligence and Machine Learning technologies [1] Group 2 - The article does not provide any financial performance data or specific investment recommendations related to Compugen Ltd. [2][3]

Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

Group 1: Phio Pharmaceuticals Corp. - Phio Pharmaceuticals Corp. is an immuno-oncology biotech company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 14.4% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 0.66, significantly lower than the industry average of 7.20 [2] Group 2: Transportadora de Gas del Sur S.A. - Transportadora de Gas del Sur S.A. is a midstream energy company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 4.6% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 19.11, which is comparable to the S&P average of 19.13 [3]

As filed with the Securities and Exchange Commission on January 16, 2024. Registration No. 333-274885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 86-2967193 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...